Medical devices; immunology and microbiology devices; classification of gene expression profiling test system for breast cancer prognosis. Final rule.
The Food and Drug Administration (FDA) is classifying gene expression profiling test systems for breast cancer prognosis into class II (special controls). The special control that will apply to the device is the guidance document entitled "Class II Special Controls Guidance Document: Gene Expression Profiling Test System for Breast Cancer Prognosis." The agency is classifying the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of the guidance document that will serve as the special control for this device.
D001943:Breast Neoplasms / Q000145:classification / Q000235:genetics*; D004869:Equipment Safety / Q000145:classification*; D005260:Female; D020869:Gene Expression Profiling / Q000145:classification / Q000295:instrumentation*; D006801:Humans; D011379:Prognosis; D014481:United States; D014486:United States Food and Drug Administration